Zhaoke Ophthalmology's share price surged by over 9%, reaching a new high in the past year and a half.

Zhouke Ophthalmology-B rose by 9.15% to HK$3.22, reaching a new high in nearly one and a half years since January 8 last year. Zhouke Ophthalmology-B announced last night that the U.S. Food and Drug Administration has approved the company's new drug clinical trial application for the use of ciclosporin eye gel in the treatment of moderate to severe dry eye syndrome.